Zacks Downgrades Jazz Pharmaceuticals Plc to Neutral (JAZZ)
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a report issued on Wednesday, Stock Ratings News reports. They currently have a $148.80 price objective on the stock. Zacks‘ price target indicates a potential upside of 2.28% from the stock’s previous close.
A number of other firms have also recently commented on JAZZ. Analysts at UBS AG raised their price target on shares of Jazz Pharmaceuticals Plc from $130.00 to $164.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at R. F. Lafferty downgraded shares of Jazz Pharmaceuticals Plc from a “buy” rating to a “neutral” rating in a research note to investors on Tuesday. They now have a $140.00 price target on the stock. Finally, analysts at Brean Capital raised their price target on shares of Jazz Pharmaceuticals Plc to $171.00 in a research note to investors on Friday, December 20th. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $115.93.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) traded up 1.75% on Wednesday, hitting $148.0275. The stock had a trading volume of 757,650 shares. Jazz Pharmaceuticals Plc has a 52 week low of $50.76 and a 52 week high of $148.14. The stock has a 50-day moving average of $122.6 and a 200-day moving average of $94.88. The company has a market cap of $8.554 billion and a price-to-earnings ratio of 24.72.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $1.78 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.67 by $0.11. The company had revenue of $232.20 million for the quarter, compared to the consensus estimate of $227.38 million. During the same quarter last year, the company posted $1.29 earnings per share. Jazz Pharmaceuticals Plc’s revenue was up 32.3% compared to the same quarter last year. On average, analysts predict that Jazz Pharmaceuticals Plc will post $6.37 earnings per share for the current fiscal year.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.